2013
Ipilimumab-induced Perforating Colitis
Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced Perforating Colitis. Journal Of Clinical Gastroenterology 2013, 47: 781-785. PMID: 23632354, PMCID: PMC6091636, DOI: 10.1097/mcg.0b013e31828f1d51.Peer-Reviewed Original ResearchConceptsIpilimumab-induced colitisSteroid therapyHistologic findingsT-lymphocyte-associated antigen 4Common side effectsAssociated histologic findingsBowel perforationSubtotal colectomyMucosal biopsiesSegmental resectionStandard treatmentAntigen-4Metastatic melanomaColitisSide effectsMonoclonal antibodiesTherapyIpilimumabColectomyDiarrheaPatientsPerforationTreatmentResectionBiopsy
2005
Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation
Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation. Clinical Cancer Research 2005, 11: 4827-4834. PMID: 16000580, DOI: 10.1158/1078-0432.ccr-04-2510.Peer-Reviewed Original ResearchConceptsAntitumor responseTumor tissueAntitumor activityMajor antitumor responsesTumor-bearing dogsDose-limiting toxicityInherent antitumor activitySignificant antitumor activityRefractory feverDisease stabilizationEscalation trialFirst infusionShort-term toxicityIncisional biopsyClinicopathologic variablesSystemic administrationTumor targeting capacityMalignant tumorsAcute deathSpontaneous tumorsSpontaneous neoplasiaPowerful anticancer therapySalmonella typhimuriumVital signsPhase I